Feline Heartworm Disease

Feline Heartworm Disease (FHD) is a serious, potentially life-threatening parasitic infection in cats caused by Dirofilaria immitis, the same nematode responsible for canine heartworm disease. Unlike dogs, cats are atypical (resistant) hosts, meaning the majority of larvae fail to reach full maturity; however, even immature worms can cause profound inflammatory and cardiopulmonary pathology [1]. The disease is distributed wherever the mosquito vectors capable of transmitting the parasite are endemic, including much of the southern United States and many other warm, humid regions worldwide. Because clinical signs can mimic other common feline respiratory or gastrointestinal conditions, FHD is frequently underdiagnosed or misidentified [1].

Causative Agent: FHD is caused by Dirofilaria immitis, a filarial nematode transmitted exclusively through the bites of infected mosquitoes (Aedes, Culex, and Anopheles spp.). Cats are considered aberrant or resistant hosts compared to dogs [1].

Transmission and Life Cycle: When an infected mosquito feeds on a cat, it deposits infective third-stage larvae (L3) into the skin. These larvae molt through L4 and then into immature adult stages (L5). In cats, the majority of larvae are destroyed by the host immune response during early migration, but those that survive reach the pulmonary vasculature approximately 70–90 days post-infection. Adult worms (when they do mature) tend to be fewer in number (typically 1–3 worms), smaller in size, and shorter-lived in cats than in dogs.

Pathological Mechanism: The cardiopulmonary pathology of FHD is driven by two distinct phases:

1. ·

   Heartworm-Associated Respiratory Disease (HARD): Even immature worms arriving in the pulmonary vasculature trigger a severe local eosinophilic and neutrophilic inflammatory response. This causes pulmonary arteritis, vascular endothelial damage, and bronchointerstitial pneumonitis — a syndrome now recognized as HARD. This inflammatory phase accounts for many of the acute respiratory signs and explains why antigen-negative cats can still be severely ill.

2. ·

   Adult Worm Burden and Death: If worms survive to adulthood, they lodge in the right heart and proximal pulmonary arteries. Their presence, and especially their death (which may be spontaneous), triggers acute severe thromboembolism and anaphylactoid reactions, which can cause sudden death. Because cats have a smaller cardiovascular system than dogs, even one or two dying worms can be catastrophic.

Risk Factors:

• ·Living in or traveling to mosquito-endemic regions [1]
• ·Outdoor or indoor-outdoor lifestyle (though indoor cats are not fully protected)
• ·No prior heartworm preventive use
• ·The multicenter study enrolled cats over 6 months of age presenting with cough, dyspnea, or vomiting — underscoring that any adult cat in an endemic area is at risk [1]

Diagnosis of FHD is challenging because no single test has perfect sensitivity and specificity in this species. A multimodal diagnostic approach is essential [1].

Clinical Presentation: Cats presenting with coughing, dyspnea, or unexplained vomiting in heartworm-endemic areas should be evaluated for FHD, as highlighted by the multicenter study design [1].

Serological Testing:

• ·Antigen Testing (Ag): Detects adult female worm antigen. In the multicenter study, the DiroCHEK antigen test was used; however, antigen tests have significantly lower sensitivity in cats than in dogs because worm burdens are low, worms may be male-only or immature, and female worms may be absent. A negative antigen test does NOT rule out FHD [1].
• ·Antibody Testing (Ab): Detects the host immune response to D. immitis larvae and adults. Antibody tests (including those by Animal Diagnostics and Heska evaluated in the multicenter study) are more sensitive in cats than antigen tests and indicate exposure, but cannot confirm active adult infection [1]. A combined approach using both antigen and antibody testing is currently recommended; a positive antibody test with a negative antigen test still warrants further workup [1].
• ·Microfilaria Testing (Knott's or DIFIL test): Rarely positive in cats due to the low likelihood of reproductive adult pairs and the rapid immune-mediated clearance of microfilariae; a negative result does not exclude infection [1].

Thoracic Radiography: Radiographs were part of the multicenter diagnostic protocol [1]. Classic findings include:

• ·Enlarged, tortuous, or blunted pulmonary arteries (particularly the caudal lobar arteries)
• ·Peribronchial and interstitial infiltrates
• ·Hyperinflation (consistent with air trapping due to airway inflammation)
• ·Pleural effusion in severe cases

Echocardiography: Ultrasound visualization of worms (hyperechoic parallel lines) within the right ventricle or pulmonary arteries is highly specific when positive, but sensitivity is operator-dependent and worms are not always in visualizable positions.

Laboratory Findings: Complete blood count (CBC) and serum chemistry may support the diagnosis [1]:

• ·Eosinophilia: Elevated eosinophil count is a common but inconsistent finding; its absence does not exclude disease
• ·Basophilia: May be observed in some cases of active infection
• ·HCT: May be normal or mildly decreased (anemia of chronic disease)
• ·Hyperglobulinemia (elevated GLOB): Reflects chronic immune stimulation
• ·ALT: May be mildly elevated in some patients with systemic involvement
• ·BUN/CREA: Generally within normal limits unless concurrent renal disease exists
• ·PLT: Thrombocytopenia can occur secondary to pulmonary thromboembolism and consumption

Bronchoscopy / Bronchoalveolar Lavage (BAL): BAL may reveal eosinophilic inflammation, supporting HARD, though it is not specific for D. immitis.

There is no universally accepted, fully safe curative treatment protocol for FHD in cats, making management largely supportive. The adulticide melarsomine dihydrochloride (used in dogs) is contraindicated in cats due to the high risk of fatal pulmonary thromboembolism from rapid worm kill in the feline cardiovascular system.

Supportive and Symptomatic Management (Preferred Approach):

• ·Corticosteroids: Prednisolone is the cornerstone of medical management. It reduces pulmonary inflammation, decreases the severity of HARD, and mitigates the inflammatory response to dying worms. Typical protocols involve short courses or tapering regimens based on clinical response. Corticosteroids are particularly indicated during acute respiratory crises.
• ·Bronchodilators: May be used adjunctively for cats with significant bronchoconstriction (e.g., terbutaline, theophylline).
• ·Diuretics: If pleural effusion is present and contributing to respiratory compromise, thoracocentesis and/or diuretic therapy (furosemide) may be employed.
• ·Oxygen Supplementation: Required during acute dyspnoeic episodes.
• ·Aspirin: Has been used historically at low doses for its antiplatelet effects to reduce pulmonary arterial thromboembolism; however, its use is controversial and requires careful consideration given feline aspirin sensitivity.
• ·Activity Restriction: Strict rest is recommended to reduce cardiopulmonary demand, particularly in the period surrounding potential worm death.

Surgical Worm Removal: In cats with severe right-sided heart failure or caval syndrome caused by visible worms in the right heart or great vessels, surgical extraction via jugular venotomy (using flexible alligator forceps under fluoroscopic or echocardiographic guidance) may be performed. This carries significant anesthetic and procedural risk but can be life-saving when worms are located and accessible.

Macrocyclic Lactones (Preventive Doses): Ivermectin or selamectin at preventive doses are NOT adulticidal but may reduce larval burden over time and prevent new infections. Some clinicians use them as part of a long-term management strategy, combined with corticosteroids during anticipated larval arrival periods.

Monitoring During Treatment: Regular thoracic radiographs, repeat serology, and CBC monitoring are important to assess treatment response and detect complications such as pulmonary thromboembolism.

The prognosis for FHD in cats is variable and depends heavily on worm burden, the stage of infection at diagnosis, and the severity of cardiopulmonary involvement at presentation [1].

Key Prognostic Points:

• ·Cats presenting with acute severe dyspnea, collapse, or signs of thromboembolism carry a grave short-term prognosis, as sudden death can occur even with treatment [1].
• ·The multicenter study by Dillon et al. (2000) enrolled cats presenting specifically with coughing, dyspnea, vomiting unrelated to eating, or acute death — highlighting that sudden death is a recognized and documented clinical outcome of FHD, and that cats may present in extremis or be found dead without prior warning [1].
• ·Cats with milder, chronic respiratory signs (e.g., episodic coughing managed with corticosteroids) may survive for months to years with appropriate supportive care, as adult worm lifespans in cats are shorter (approximately 2–3 years, compared to 5–7 years in dogs), meaning the disease may "self-resolve" if the cat survives the critical period of worm death.
• ·Antigen-positive cats (confirmed adult infection) are at higher immediate risk than antibody-positive/antigen-negative cats (exposure without confirmed adult infection), though the latter group is not without risk due to HARD.
• ·Mortality associated with the acute thromboembolism event following worm death is a significant concern, and owners must be counseled about the risk of sudden deterioration or death even in apparently stable patients.

Note: The referenced literature (Dillon et al., 2000 [1]) provides clinical and diagnostic correlations from a multicenter cohort but does not report specific numerical survival rates or actuarial mortality percentages for FHD-diagnosed cats. Precise mortality statistics (e.g., 30-day or 1-year survival rates) are not established in the cited reference, and broader veterinary literature on this topic is limited by study design heterogeneity and small cohort sizes. Clinicians should communicate prognosis on a case-by-case basis.

Prevention is the most effective and safest strategy for managing FHD, as treatment options are limited and the disease can be rapidly fatal [1].

Macrocyclic Lactone Preventives: Monthly topical or oral macrocyclic lactone products approved or commonly used for cats include:

• ·Selamectin (Revolution®) — topical, kills L3/L4 larvae, provides a broad spectrum of parasite protection
• ·Ivermectin (Heartgard® for Cats) — oral, highly effective at preventing establishment of infection
• ·Moxidectin (combined products) — available in some regions

These products work by killing migrating larvae before they can reach the pulmonary vasculature, and must be administered consistently every 30 days throughout the mosquito season (year-round in endemic regions). The multicenter study underscores the real prevalence of FHD in endemic regions such as Florida, South Carolina, Tennessee, and Texas [1], reinforcing the need for consistent prophylaxis in these areas.

Mosquito Exposure Reduction:

• ·Keeping cats indoors, especially during peak mosquito activity (dawn and dusk)
• ·Use of mosquito screens on windows and doors
• ·Eliminating standing water near the home to reduce mosquito breeding
• ·Note: Indoor cats are still at risk and should receive preventive medication; the indoor lifestyle alone is insufficient protection

Routine Screening:

• ·Annual or biannual heartworm antigen and antibody testing in endemic areas, even for cats on preventives, is recommended to detect breakthrough infections and ensure owner compliance awareness
• ·Testing before initiating preventive therapy allows establishment of a baseline [1]

No Vaccine Available: There is currently no licensed vaccine against Dirofilaria immitis infection in cats. Prevention is entirely reliant on pharmacologic prophylaxis and environmental management.

Owner Education: Educating cat owners about the risk of FHD — including the misconception that indoor cats are fully protected — is a critical component of prevention programs, particularly in endemic geographic regions identified in clinical studies [1].